Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.97 +1.4%	$2.54	$1.78 ▼ $8.56	$62.31M	0.77	244,778 shs	128,001 shs
CUE Cue Biopharma	$0.83 +1.8%	$0.77	$0.45 ▼ $1.99	$63.48M	1.53	256,508 shs	172,800 shs
CYAD Celyad	$0.60	$0.67	$0.46 ▼ $3.07	$15.91M	N/A	N/A	3,009 shs
IFRX InflaRx	$0.91 +1.7%	$0.84	$0.71 ▼ $2.82	$61.32M	1.29	396,313 shs	601,397 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+5.40%	+5.78%	+9.74%	+32.58%	-59.25%
CUE Cue Biopharma	+0.37%	+2.71%	-9.74%	+22.68%	-10.35%
CYAD Celyad	0.00%	0.00%	0.00%	0.00%	0.00%
IFRX InflaRx	+0.57%	+8.55%	+6.31%	-51.46%	-37.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	3.9572 of 5 stars	3.4	3.0	0.0	4.8	2.4	0.8	0.0
CUE Cue Biopharma	2.6927 of 5 stars	0.0	5.0	0.0	4.7	2.9	0.8	0.6
CYAD Celyad	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	2.5916 of 5 stars	3.5	4.0	0.0	0.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.75	Moderate Buy	$19.75	564.98% Upside
CUE Cue Biopharma	0.00	N/A	N/A	N/A
CYAD Celyad	0.00	N/A	N/A	N/A
IFRX InflaRx	3.00	Buy	$6.60	622.50% Upside

Current Analyst Ratings Breakdown

Latest CYAD, CUE, ADVM, and IFRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
5/29/2025	IFRX InflaRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	62.31	N/A	N/A	($0.96) per share	-3.09
CUE Cue Biopharma	$8.29M	7.66	N/A	N/A	$0.24 per share	3.44
CYAD Celyad	$200K	79.56	N/A	N/A	$0.02 per share	30.00
IFRX InflaRx	$180K	340.68	N/A	N/A	$0.96 per share	0.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$7.85	N/A	N/A	N/A	N/A	-297.29%	-101.40%	11/3/2025 (Estimated)
CUE Cue Biopharma	-$40.67M	-$0.56	N/A	N/A	N/A	-469.35%	-230.13%	-111.16%	N/A
CYAD Celyad	-$6.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	-$49.85M	-$0.80	N/A	N/A	N/A	N/A	-71.76%	-57.68%	N/A

Latest CYAD, CUE, ADVM, and IFRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	-$2.34	-$0.10	-$2.34	N/A	N/A
8/12/2025	Q2 2025	CUE Cue Biopharma	-$0.13	-$0.09	+$0.04	-$0.09	$2.00 million	$2.95 million
8/7/2025	Q2 2025	IFRX InflaRx	-$0.24	-$0.24	N/A	-$0.24	$0.02 million	$0.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
CYAD Celyad	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	1.54	1.54
CUE Cue Biopharma	0.01	1.60	1.60
CYAD Celyad	1.49	2.29	2.14
IFRX InflaRx	N/A	4.10	3.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
CUE Cue Biopharma	35.04%
CYAD Celyad	N/A
IFRX InflaRx	42.39%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
CUE Cue Biopharma	10.78%
CYAD Celyad	0.94%
IFRX InflaRx	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.98 million	19.73 million	Optionable
CUE Cue Biopharma	60	76.85 million	68.56 million	Optionable
CYAD Celyad	95	26.52 million	26.28 million	Not Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable

CYAD, CUE, ADVM, and IFRX Headlines

Recent News About These Companies

InflaRx Announces Participation in September Investor Conferences

August 21 at 9:30 AM | markets.businessinsider.com

InflaRx Announces Participation in September Investor Conferences

August 21 at 7:30 AM | globenewswire.com

InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates

August 7, 2025 | zacks.com

InflaRx Reports Significant Losses in H1 2025 Financials

August 7, 2025 | tipranks.com

InflaRx N.V. Announces Upcoming Data Readouts for INF904 in CSU and HS, Financial Results for Q2 2025, and Updates on Vilobelimab and BDB-001 Developments

August 7, 2025 | quiverquant.comQ

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | globenewswire.com

InflaRx (IFRX) to Release Earnings on Thursday

August 2, 2025 | marketbeat.com

InflaRx (NASDAQ:IFRX) Trading 2.8% Higher - What's Next?

August 1, 2025 | marketbeat.com

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

July 31, 2025 | globenewswire.com

InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected

July 25, 2025 | msn.com

InflaRx Announces Receipt of Nasdaq Deficiency Notice ... - Morningstar

July 12, 2025 | morningstar.comM

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum ...

July 12, 2025 | seekingalpha.com

InflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

July 12, 2025 | finanznachrichten.de

InflaRx N.V. Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Requirement

July 11, 2025 | quiverquant.comQ

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

July 11, 2025 | globenewswire.com

InflaRx N.V. (IFRX) Latest Stock News & Headlines - Yahoo Finance

July 4, 2025 | finance.yahoo.com

InflaRx Appoints KPMG as New Auditor Following Shareholder Approval

June 27, 2025 | tipranks.com

InflaRx stock rating cut, price target slashed to $2 by Raymond James

May 30, 2025 | investing.com

InflaRx Earnings Estimates, EPS & Revenue | NASDAQ:IFRX | Benzinga

May 30, 2025 | benzinga.com

InflaRx’s Strategic Shift to INF904: A Promising Focus Amidst Early-Stage Uncertainty

May 29, 2025 | tipranks.com

InflaRx N.V.: InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 28, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYAD, CUE, ADVM, and IFRX Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.97 +0.04 (+1.37%)

Closing price 04:00 PM Eastern

Extended Trading

$2.94 -0.03 (-0.84%)

As of 05:58 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Cue Biopharma NASDAQ:CUE

$0.83 +0.01 (+1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$0.83 +0.00 (+0.48%)

As of 04:33 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Celyad NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

InflaRx NASDAQ:IFRX

$0.91 +0.02 (+1.73%)

Closing price 04:00 PM Eastern

Extended Trading

$0.94 +0.03 (+2.79%)

As of 07:03 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time